TickerFacts.

Aligos Therapeutics, Inc. (ALGS): Shareholders' Equity

Annual figures by period end, from SEC filings.

$53.55M
As of 2025-12-31
$31.88M
As of 2026-06-30
-19.8%
3-year compound annual growth
-24.6%
5-year compound annual growth
$220.04M2019-12-31: -$64.89M2020-12-31: $220.04M2021-12-31: $184.73M2022-12-31: $103.90M2023-12-31: $92.08M2024-12-31: -$28.97M2025-12-31: $53.55M$53.55M
2019-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$53.55Mn/m2026-03-05, Balance as of period end
2024-12-31-$28.97Mn/m2026-03-05, Balance as of period end
2023-12-31$92.08M-11.4%2025-03-10, Balance as of period end
2022-12-31$103.90M-43.8%2024-03-12, Balance as of period end
2021-12-31$184.73M-16.0%2023-03-09, Balance as of period end
2020-12-31$220.04Mn/m2022-03-10, Balance as of period end
2019-12-31-$64.89Mn/a2021-03-23, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Aligos Therapeutics, Inc. (ALGS)2025-12-31$53.55Mn/m
Humacyte, Inc. (HUMA)2025-12-31$3.11Mn/m
Dyadic International Inc (DYAI)2025-12-31$1.23M-50.1%
Outlook Therapeutics, Inc. (OTLK)2025-09-30-$32.19Mn/m
Surrozen, Inc. (SRZN)2025-12-31-$187.76Mn/m
CRISPR Therapeutics AG (CRSP)2025-12-31$1.92B-0.5%
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31$8.10M-18.8%
Inhibrx Biosciences, Inc. (INBX)2025-12-31$7.99M-94.0%
CG Oncology, Inc. (CGON)2025-12-31$752.60M+2.6%

Compare ALGS, HUMA, DYAI, OTLK side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗